Hernychova L, Dvořáková P, Michalova E, Vojtěšek B
Klin Onkol. 2014;27 Suppl 1:S98-103. doi: 10.14735/amko20141s98.
Cancers are genetically and clinically very heterogeneous diseases; therefore, various proteomic studies have been trying to find bio-markers which can facilitate prognosis, diagnosis or treatment of these oncological diseases. The mass spectrometry is an effective tool for identification, quantitation, and characterization of biomolecules in the complex bio-logical samples. The first step suitable for selection of bio-markers called discovery proteomics provides a detailed analysis of the samples contributing to the identification of proteins, comparison of their presence in the samples, and selection of the convenient candidates for the prospective bio-markers. The next step of proteomics analysis is directed towards verification of chosen bio-markers with the approach called targeted proteomics. This technique evaluates presence and quantity of the proteins (biomarkers) in clinically precisely defined samples. This article focuses on the description of various approaches suitable for the quantitative analysis of the proteins connected with mass spectrometry.
癌症是基因和临床方面都高度异质性的疾病;因此,各种蛋白质组学研究一直在试图寻找能够促进这些肿瘤疾病的预后、诊断或治疗的生物标志物。质谱分析法是用于识别、定量和表征复杂生物样本中生物分子的有效工具。适用于生物标志物选择的第一步,即发现蛋白质组学,对样本进行详细分析,有助于蛋白质的识别、比较它们在样本中的存在情况,以及选择方便的候选前瞻性生物标志物。蛋白质组学分析的下一步是采用靶向蛋白质组学方法对所选生物标志物进行验证。该技术评估临床精确定义样本中蛋白质(生物标志物)的存在情况和数量。本文重点描述适用于与质谱分析法相关的蛋白质定量分析的各种方法。